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Abstract
Background: Arterial peripheral disease is a condition caused by the blocked blood flow resulting from arterial
cholesterol deposits within the arms, legs and aorta. Studies have shown that macrophages in atherosclerotic
plaque are highly activated, which makes these cells important antigen-presenting cells that develop a specific
immune response, in which LDLox is the inducing antigen. As functional changes of cells which participate in the
atherogenesis process may occur in the peripheral blood, the objectives of the present study were to evaluate
plasma levels of anti-inflammatory and inflammatory cytokines including TNF-a, IFN-g, interleukin-6 (IL-6), IL-10 and
TGF-b in patients with peripheral arteriosclerosis obliterans, to assess the monocyte activation level in peripheral
blood through the ability of these cells to release hydrogen peroxide (H2O2) and to develop fungicidal activity
against Candida albicans (C. albicans) in vitro.
Methods: TNF-a, IFN-g, IL-6, IL-10 and TGF-b from plasma of patients were detected by ELISA. Monocyte cultures
activated in vitro with TNF-alpha and IFN-gamma were evaluated by fungicidal activity against C. albicans by
culture plating and Colony Forming Unit (CFU) recovery, and by H2O2 production.
Results: Plasma levels of all cytokines were significantly higher in patients compared to those detected in control
subjects. Control group monocytes did not release substantial levels of H2O2 in vitro, but these levels were
significantly increased after activation with IFN-g and TNF-a. Monocytes of patients, before and after activation,
responded less than those of control subjects. Similar results were found when fungicidal activity was evaluated.
The results seen in patients were always significantly smaller than among control subjects. Conclusions: The results
revealed an unresponsiveness of patient monocytes in vitro probably due to the high activation process occurring
in vivo as corroborated by high plasma cytokine levels.
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Background
Arterial peripheral disease is a condition caused by the
blocking of blood flow as a result of cholesterol deposi-
tion in the arteries of the arms, legs and aorta [1].
Evidence suggests that low-density lipoprotein (LDL)
modified by oxidation (LDLox) is the main triggering fac-
tor of the lesion. After the oxidation process, these parti-
cles become cytotoxic to endothelial cells, which once
damaged, start to express and produce adhesion mole-
cules and chemokines, leading to monocyte recruitment
and adherence [2,3].
Studies have shown that macrophages in the athero-
sclerotic plaque are highly activated, followed by an
increase in the expression of class II molecules of the
major histocompatibility complex. This process makes
macrophages important antigen-presenting cells for devel-
oping a specific immune response. In this case LDLox is
the inducing antigen which causes a Th1 response, fol-
lowed by production of interferon- gamma (IFN-g)a n d
tumor necrosis factor -alpha and -beta (TNF-a and TNF-
b) and interleukin-12 (IL-12) [4-7]. Thus, IFN-g has been
considered one of the main cytokines released during
atherosclerosis which, through an activation process of
macrophages, amplifies the actions of these cells but in
certain circumstances may lead to apoptosis [8].
Given the fact that the functional changes in the cells
that participate in the atherogenesis process may occur
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were to evaluate the plasma levels of anti-inflammatory
and inflammatory cytokines including interleukin-6 (IL-
6), IFN-g, IL-10 and transforming growth factor-beta
(TGF-b) in patients with peripheral arteriosclerosis
obliterans, to assess the level of monocyte activation in
the peripheral blood through the ability of these cells to
release hydrogen peroxide (H2O2) and to develop fungi-
cidal activity against Candida albicans (C. albicans) in
vitro.
Patients and methods
Patients
The present study was performed on ten male subjects,
aged over 60 years, with moderate intermittent claudica-
tion, who were seen at the first time in the ambulatory of
the Peripheral Vascular Surgery Service at the Clinic
Hospital of the Botucatu Medical School - UNESP, Brazil.
For this study both control subjects and patients were
evaluated and excluded for presenting any of the follow-
ing criteria: using medications, suffering from systemic
arterial hypertension or any chronic disease, drinking
alcohol or smoking.
The clinical diagnosis was performed by the ankle-bra-
chial pressure index and exercise stress test. Using the
same criteria, ten male subjects over 60 years old, with
no peripheral arterial disease were also evaluated as the
control group. All subjects were informed of the proce-
dures and objectives of the study and signed a written
informed consent. The study protocol was approved by
the local Research Ethics Committee (653/00).
Blood samples collected both from patients and control
subjects were placed in tubes containing heparin for bio-
chemical analysis, cytokine measurement and the isolation
and culturing of monocytes.
Isolation of peripheral blood mononuclear cells
Heparinized venous blood samples were obtained from
patients and healthy donors. Peripheral blood mononuc-
lear cells (PBMC) were isolated by density gradient centri-
fugation at 400 g for 30 min on Ficoll-Paque™ Plus
[density (d) = 1.077] (GE Healthcare Bio-Sciences AB,
Uppsala). Briefly, 20 mL of heparinized blood was mixed
with an equal volume of RPMI - 1640 tissue culture med-
ium (Sigma-Aldrich, St. Louis, USA), and samples were
layered over 10 mL of Ficoll-Paque™ Plus in a 50 mL con-
ical plastic centrifuge tube. After centrifugation at 400 g
for 30 min at room temperature, the interface layer of
PBMC was harvested and washed twice with RPMI - 1640
tissue culture medium (Sigma-Aldrich). The PBMC sus-
pension was stained with neutral red (0.02%) which is
incorporated by monocytes and allows their identification
and counting in a hemocytometer chamber. After count-
ing, the suspension of mononuclear cells was adjusted to
2×1 0
6 monocytes/mL in RPMI-1640 (Sigma-Aldrich)
containing 2 mM L-glutamine, 10% heat-inactivated
human autologous serum, 20 mM HEPES and 40 μg/mL
gentamicin (Complete Tissue Culture Medium - CTCM),
dispensed at 100 μL/well in 96-well flat-bottomed plates
(TPP, Trasadingen, Switzerland) and used for evaluation
of fungicidal activity and H2O2 production. After incuba-
tion of cultures for 2 h at 37°C in 5% CO2,n o n - a d h e r e n t
cells were removed by aspiration and each well was rinsed
twice with RPMI - 1640 tissue culture medium. The
resulting monocyte cultures were treated with the follow-
ing stimuli for 18 h at 37°C in 5% CO2:( i )C T C M ,( i i )
CTCM + IFN-g human recombinant, or (iii) CTCM +
TNF-a human recombinant (all from R&D Systems, Min-
neapolis, MN, USA) at different concentrations.
Fungicidal activity of monocytes against C. albicans
Yeast cells of C. albicans, sample H-428/03, originally iso-
lated from a patient of the Clinical Hospital of the Botu-
catu Medical School - UNESP, Brazil, and maintained by
weekly subcultivation in yeast form at 35°C on BHI agar
medium (Oxoid, Ltd.), were used after 5 or 6 days of
growth.
After 18 h of incubation at 37°C in 5% CO2, superna-
tants from monocyte cultures, either activated with IFN-
g and TNF-a or not, were discarded and monocytes
monolayers were challenged with 100 μLo fC. albicans
suspension containing 8 × 10
4 viable yeasts/mL (fungus-
to-monocyte ratio of 1:25) prepared in CTCM plus 10%
fresh autologous serum, as the source of complement
for yeast opsonization, for 2.5 h at 37°C in 5% CO2.
After the incubation period, culture supernatants were
collected and the monocyte monolayers were washed
several times with sterile distilled water to remove and
to lyse monocytes with subsequent release of live fungi.
Each well washing resulted in a final volume of 4.0 mL,
and 0.1 mL was plated on brain-heart infusion (BHI)
agar medium (OXOID). Inoculated plates, in triplicates
of each culture, were incubated at 37°C, for 24 hours, in
sealed plastic bags to prevent drying. After 10 days, the
number of colony forming units (CFU) per plate was
counted. The inoculum used for the challenge was also
plated under the same conditions. The plates containing
the material obtained from the monocyte-fungus cul-
tures were labeled experimental plates and those with
the inoculum alone were used as controls. Fungicidal
activity percentage was determined by the following
formula:
%F u n g i c i dal Activity = [1-(mean CFU recovered on experimental plates/mean CFU recovered on control plates)]×100
Determination of hydrogen peroxide release (H2O2)
The production of H2O2 was determined according to
the method described by Pick & Keisari (1980) and
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incubation period, supernatants of monocyte cultures,
either activated or not with cytokines, were discarded
and the cells were resuspended to the original volume
in phenol red solution containing 140 mM of NaCl;
10 mM of phosphate buffered saline (pH 7) 5.5 mM of
dextrose; 0.56 mM phenol red; 0.01 mg/mL of horserad-
ish peroxidase, type II (Sigma, Chemical Co USA) and
1 ug of Phorbol Mirestate Acetate (PMA). Plates were
incubated in a humidified chamber for 1 h in 5 % CO2
at 37°C. The reaction was then halted by the addition of
10 mL of 1 M NaOH and the absorbance at 620 nm
was determined with a micro-ELISA reader (MD 5000,
Dynatech Laboratories, Inc., Chantilly, VA., U.S.A.).
Results were expressed as nanomoles of H2O2/2 × 10
5
cells using the standard curve established in each assay
composed of known molar concentrations of H2O2 in
phenol red buffer solution. In these experimental condi-
tions, the curve was constructed based on these concen-
trations: 0.5; 1.0; 1.5 and 2.0 nM of H2O2.
Plasma measurements of IL-6, TNF-a, IFN-g, IL-10 and
TGF-b
Plasma was separated from cell debris, by centrifuging at
1000 × g for 15 min, and stored at -70°C. The IL-6,
TNF-a,I F N - g,I L - 1 0a n dT G F - b concentrations were
measured by capture ELISA using the Quantikine
ELISA kit (R&D Systems, Minneapolis, MN, USA).
ELISA was performed according to the manufacturer’s
protocol. Cytokine concentrations were determined
according to a standard curve for serial two-fold dilu-
tions of human recombinant cytokines. Absorbance
values were measured at 492 nm using a micro-ELISA
reader (MD 5000, Dynatech Laboratories). The lower
limit of IL-6, TNF-a,I F N - g, IL-10 and TGF-b detection
was 5.0 pg/mL.
Biochemical analyses
The analysis of cholesterol, triglycerides, HDL cholesterol,
LDL cholesterol, glucose, urea, creatinine, alanine amino-
transferase (ALT) and aspartate aminotransferase (AST)
was performed using colorimetric enzymatic kits (CELM).
C-reactive protein (CRP) was measured by dry chem-
istry (Vitros 950 analyzer, Johnson & Johnson) and
alpha-1-acid glycoprotein (a1-AGP) by nephelometry
(Boehringer Nephelometer).
Statistical Analysis
Monocyte activation-level results were evaluated by ana-
lysis of variance (ANOVA) for dependent samples, and
mean values were compared using the Tukey-Kramer
test for multiple comparisons [11].
Data from cytokines, biochemical evaluation, and lipid
profile were assessed by the Student’s t test.
All statistical analyses were performed using the soft-
ware Graph Pad InStat 3.05 (Graph Pad Software, San
Diego, CA, USA) at 5% significance level.
Results
Concentrations of plasma biochemical tests
Results on the plasma levels of glucose, alanine amino-
transferase (ALT), aspartate aminotransferase (AST),
urea and creatinine of patients and control subjects are
shown in Table 1. Patients and control subjects pre-
sented levels within the normal range. Thus, no signifi-
cant difference was found between patients and control
subjects in the comparative analyses of all parameters
evaluated. This finding shows that most subjects evalu-
ated in this study did not show any sign suggestive of
diabetes or of liver or kidney problems.
Results concerning total plasma cholesterol, triglyceride,
HDL and LDL are also shown in Table 1. Therefore, total
plasma cholesterol of both control subjects and patients
was above normal levels for most subjects. Triglyceride
levels of control subjects and patients were normal. HDL
levels of most control subjects were normal, while all
patients had levels outside of the normal range. LDL levels
were observed to be significantly higher in patients than in
control subjects.
Plasma levels of a1-AGP (a1-acid glycoprotein) and
CRP (C-reactive protein) are also shown in Table 1. The
analysis of these findings revealed higher levels of these
two proteins in patients than in the control group.
Table 1 Concentrations of plasma glucose, alanine
aminotransferase, aspartate aminotransferase, urea,
creatinine, total cholesterol, triglyceride, HDL cholesterol,
LDL cholesterol, alpha 1-acid glycoprotein (a1- AGP) and
C-reactive protein (CRP) presented by control subjects
and patients
Control subjects Patients
Glucose (mg/dL) 88.57 ± 2.46 92.42 ± 2.97
Alanine aminotransferase (U/L) 18.85 ± 2.76 20.42 ± 2.77
Aspartate aminotransferase (U/L) 16.57 ± 3.45 15.42 ± 3.77
Urea (mg/dL) 30.57 ± 2.53 36.14 ± 2.82
Creatinine (mg/dL) 1.1 ± 0.03 1.08 ± 0.05
Cholesterol (mg/dL) 201.4 ± 20.12 203.7 ± 20.32
Triglyceride (mg/dL) 107 ± 18 132 ± 22.4
HDL cholesterol (mg/dL) 54.0 ± 4.5 38.14 ± 3.2*
LDL cholesterol (mg/dL) 123.71 ± 6.9 163.14 ± 9.0*
a1-AGP (mg/dL) 76.71 ± 3.59 112.42 ± 8.71*
CRP (mg/dL) 0.10 ± 0 0.27 ± 0.60*
Normal values - glucose: 70-110 mg/dL; alanine transaminase: 30-65 U/L; aspartate
transaminase: 15-37 U/L; urea: 15-40 mg/dL; creatinine: 0.6-1.4 mg/dL; cholesterol:
< 200 mg/dL; triglyceride: < 200 mg/dL; HDL cholesterol: > 55 mg/dL; LDL
cholesterol: < 100 mg/dL; a1-acid glycoprotein (a1-AGP): 30-120 mg/dL; C-reative
protein (CRP): < 0.9 mg/dL. The results are expressed as mean ± SEM obtained
from 10 patients and 10 control subjects. *p < 0.05 × Control Group
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Plasma levels of IL-6, TNF-a and IFN-g were significantly
higher in patients; the levels of the anti-inflammatory
cytokines IL-10 and TGF-b revealed similar findings.
Thus, plasma levels of the all cytokines analyzed were
significantly higher in patients than in control subjects
(Table 2).
Fungicidal activity of monocytes against C. albicans
The ability of monocytes from control subjects and
patients to develop fungicidal activity against C. albicans
in vitro was evaluated before and after incubation with
two cytokines involved in the activation process of these
cells, namely IFN-g and TNF-a. Results from IFN-g and
TNF-a are shown in Figures 1 and 2, respectively.
As to IFN-g assays (Figure 1), non-activated mono-
cytes of control subjects showed a significant fungicidal
activity when compared to patients. The cytokine stimu-
lation, especially at 100 units/mL, promoted a higher
fungicidal activity when compared to non-activated
cells. Monocytes of patients showed a response profile
similar to that of control subjects, but with significantly
lower response levels at all doses when compared to the
ones from control subjects, before and after the activa-
tion process.
Similar findings were found in TNF-a assays (Figure 2);
the non-activated monocytes of control subjects showed a
significant fungicidal activity when compared to patients.
The cytokine stimulation, mainly at 100 units/mL,
promoted a higher fungicidal activity when compared to
non-activated cells. Monocytes of patients also showed a
response profile similar to that of control subjects when
activated with TNF-a, but also with inferior response
levels. Nevertheless, the results gathered from patients
were always lower than those from the control group.
Hydrogen peroxide (H2O2) production by activated
monocytes
Similarly to the activation assays for evaluation of fungi-
cidal activity, the levels of H2O2 released by monocytes
from control subjects and patients were evaluated before
and after IFN-g and TNF-a activation.
In IFN-g assays (Figure 3), non-activated monocytes of
control subjects released substantial levels of the meta-
bolite which increased significantly after activation, espe-
cially at the concentration of 100 U/mL, which agrees
with the fungicidal activity assays. The response profile
Table 2 Concentrations of plasma cytokines (pro- and
anti-inflammatory) in control subjects and patients
Control subjects Patients
IL-6 (pg/mL) 9.23 ± 0.44 17.7 ± 1.7 *
TNF-a (pg/mL) 2.7 ± 0.3 5.0 ± 0.5*
IFN-g (pg/mL) 181 ± 43.0 327 ± 70.0**
IL-10 (pg/mL) 10.0 ± 3.4 66.6 ± 14.3**
TGF-b (pg/mL) 105.6 ± 9.9 483.6 ± 161**
The results are expressed as mean ± SEM obtained from 10 patients and 10
control subjects. * p < 0.05 × Control Group; **p < 0.01 × Control Group
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Figure 1 Monocyte fungicidal activity against Candida albicans.
Monocytes obtained from peripheral blood of control subjects and
patients, before and after activation with different concentrations of
interferon-gamma (IFN-g), and after challenge with C. albicans. The
results are expressed as mean ± SEM and derived from triplicate
cultures of monocytes obtained from 10 patients and 10 control
subjects. *p < 0.05 × Control (CTCM); #p < 0.05 × Patient (CTCM); +
p < 0.05 × controls and patients in each group.
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Figure 2 Monocyte fungicidal activity against Candida albicans.
Monocytes obtained from peripheral blood of control subjects and
patients, before and after activation with different concentrations of
tumoral necrosis factor-alpha (TNF-a), and after challenge with C.
albicans. The results are expressed as mean ± SEM and derived from
triplicate cultures of monocytes obtained from 10 patients and 10
control subjects. *p < 0.05 × Control (CTCM); #p < 0.05 × Patient
(CTCM); + p < 0.05 × controls and patients in each group.
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control group, but with significantly lower levels found
before and after the activation process. Similar findings
were observed in TNF-a assays (Figure 4); the control
and patient cells showed an increase in H2O2 levels
after activation, mainly at the dose of 100 U/mL. How-
ever, levels of patients were always lower than those of
the controls. Trials evaluating the ability to activate
monocytes from control subjects and patients clearly
showed that patients had significantly lower responses
than those of controls, in all parameters tested.
Discussion
In the present study patients with moderate intermittent
claudication were evaluated. Results clarified the activa-
tion level of peripheral blood monocytes by analyzing
fungicidal activity against C. albicans and hydrogen per-
oxide production in vitro, and through measuring TNF-
a,I F N - g, IL-6, IL-10 and TGF-b plasma levels. This is
the first study to evaluate this process in patients with
peripheral arteriosclerosis obliterans.
We also assessed the concentrations of plasma glu-
cose, alanine aminotransferase, aspartate aminotransfer-
ase, urea, creatinine, total cholesterol, triglyceride, HDL
cholesterol, LDL cholesterol, alpha 1-acid glycoprotein
(a1- AGP) and C-reactive protein (CRP) to better char-
acterize each patient’s condition. Our results showed
that patients had diminished HDL cholesterol and ele-
vated LDL cholesterol, a1- AGP and CRP, in agreement
with the literature [12-18].
Our results demonstrated that plasma levels of all pro-
inflammatory cytokines analyzed - namely TNF-a, IFN-g
and IL-6 - were higher in these patients than those of the
control group. These results are in accord with De Palma
et al. [19] who demonstrated an increase in serum levels
of these cytokines in patients with intermittent claudica-
tion. The authors suggested that a high level of cytokines
is indicative of some complications such as claudication
followed by myocardial infarction [19].
An increased serum level of some proinflammatory
cytokines, such as TNF, has been detected in atherosclero-
tic events, including infarction and angina [20]. Neverthe-
less, Fiotti et al. [21], evaluating peripheral arterial disease,
reported that receptors of these pro-inflammatory cyto-
kines are more sensitive markers. The comparison
between patients with intermittent claudication, with
either ischemia or critical ischemia, and a control group
revealed that TNF-a and IL-1 receptors were more signifi-
cant markers than the cytokines themselves. However,
more recent studies have shown an association between
elevated TNF-a levels and peripheral arterial disease [19].
Thus, our results confirm the involvement of this cytokine
in atherosclerotic processes. We observed that patients
with higher levels of cytokines had more difficulty in the
exercise stress test, reflecting the greater degree of ische-
mia, because these patients did not show any cardiac com-
plication in contrast to reports from other authors [20,19].
Studies have also shown the role of IFN-g in modulating
the inflammatory response associated with atherosclerosis.
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Figure 3 Hydrogen Peroxide (H2O2) production by monocytes
obtained from peripheral blood of control subjects and
patients before and after activation with different
concentrations of interferon - gamma (IFN-g). The results are
expressed as mean ± SEM and derived from triplicate cultures of
monocytes obtained from 10 patients and 10 control subjects. *p <
0.05 × Control (CTCM); #p < 0.05 × Patient (CTCM); + p < 0.05 ×
controls and patients in each group.
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Figure 4 Hydrogen Peroxide (H2O2) production by monocytes
obtained from peripheral blood of control subjects and
patients before and after activation with different
concentrations of tumoral necrosis factor -alpha (TNF-a). The
results are expressed as mean ± SEM and derived from triplicate
cultures of monocytes obtained from 10 patients and 10 control
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coronary diseases such as stable and unstable angina, and
myocarditis [22]. The primary function of this cytokine is
to activate monocytes/macrophages with a consequent
increase of apoptosis, expression of adhesion molecules of
the endothelium and synthesis of other pro-inflammatory
cytokines such as IL-1 and IL-6.
Similar to results regarding pro-inflammatory cytokines,
high levels of anti-inflammatory cytokines (IL-10 and
TGF-b) were also found in patients evaluated in this
study. These findings are in agreement with others that
have shown the important anti-inflammatory function of
IL-10 during atherosclerosis. This cytokine controls cell
activation by decreasing the kappa B nuclear factor.
Another function attributed to this cytokine in the athero-
sclerotic process is its ability to control excessive cell
death by limiting the local inflammatory response. Find-
ings from studies on atherosclerotic plaque of carotid
arteries in rats confirm this function. Animals that
received IL-10 presented decreases both in pro-inflamma-
tory cytokine levels and in the apoptosis process, with the
consequent stability of the atherosclerotic plaque [23,24].
Our evaluation of monocyte activation, through the ana-
lysis of fungicidal activity against C. albicans and hydrogen
peroxide production in vitro, clearly showed that patients
had significantly lower responses than those of the control
group. These findings could be understood primarily as a
diminished activation process in these patients. However,
this idea was not confirmed by our findings showing high
levels of both pro- and anti-inflammatory cytokines in
patients’ plasma. Several studies have reported that
patients’ cells are activated and consequently present
higher capacity to release free radicals and to express
MHC class II molecules, thus increasing their antigen pre-
sentation function. This process would lead to the devel-
opment of a specific Th1 response [25]. Thus, our results
showing low monocyte responses in vitro could be inter-
preted as a high state of activation of these cells in vivo in
this stage of the disease, a process that would lead these
cells to an exhausted condition, rendering them non-
responsive in vitro. Similar studies found in the literature
showed that foam cells isolated from aortas of hypercho-
lesterolemic rats were capable of oxidizing lipoproteins,
but not able to produce reactive oxygen species in vitro
[26]. The authors suggested that this process may be
related to intense phagocytosis and lipid uptake by mono-
cytes, which would prevent them from responding to exo-
genous stimuli, with a consequent impairment of cell
functions, such as a decrease in prostaglandin production
in vitro [26,27].
In addition, natural control mechanisms of the inflam-
matory process in atherosclerosis, with a consequent inhi-
bition of phagocyte activation have been described. This
control may be related to anti-inflammatory actions of IL-
10 and TGF-b. Genetically modified mice that are incap-
able of expressing LDL receptor, after receiving a hyperch-
olesterolemic diet and transplantation of T cells, are able
to produce high levels of IL-10, which is involved in
diminishing the atherosclerotic process. The authors also
reported that IL-10 acts through mechanisms towards a
CD4
+ Th2 response that leads to an inhibition of the
macrophage activation and the apoptosis process [8].
Briefly, this study allows us to suggest that monocytes
from patients with aterosclerosis obliterans are highly
activated in vivo. This process is probably responsible for
triggering an intense inflammatory response, detected in
these patients, that nevertheless appears to be controlled
via the release of inflammatory cytokines such as IL-10.
Further studies are being undertaken in our laboratory to
elucidate these mechanisms.
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